ExoLuminate Study for Early Detection of Pancreatic Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorBiological Dynamics
About this trial
ExoLuminate is a nationally-enrolling registry study designed for earlier detection of cancer in patients at elevated risk or clinically-suspicious for pancreatic ductal adenocarcinoma (PDAC).
Those with elevated risk for PDAC can include individuals with intraductal papillary mucinous neoplasms, family history of pancreatic cancer, germline mutations in genes known to be associated with cancer, and a personal or family history of pancreatitis.
The goal of the study is to compare the performance of ExoVerita™ assay in early detection of PDAC to current standard-of-care methods of surveillance.
Eligibility criteria
Qualifiers
≥18 years old.
Meeting criteria for one of the study cohorts.
Capable of giving informed consent.
Able to provide a blood sample.
Disqualifiers
< 18 years old.
Pregnancy.
Active cancer (other than pancreatic cancer) and/or undergoing treatment for an active cancer diagnosis (except for skin malignancies).
Prior organ transplant or bone marrow transplant.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
1,000 Participants
are grouped into 8 trial groups8
Trial groupsSee each trial group below.
Sponsors and collaborators
Source ClinicalTrials.gov